NOTCH4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL15622117	1.00	1/20
SCHEMBL15622142	1.00	1/20
SCHEMBL15622692	0.91	1/20
SCHEMBL15622116	0.89	1/20
SCHEMBL15622141	0.89	1/20
SCHEMBL15621981	0.89	1/20
SCHEMBL15622436	0.89	1/20
Osugacestat (SCHEMBL12543867)	0.84	1/20
Osugacestat (SCHEMBL12543868)	0.84	1/20
Osugacestat (SCHEMBL15622455)	0.84	1/20
SCHEMBL12542524	0.80	1/20
SCHEMBL12542526	0.80	1/20
SCHEMBL12542944	0.80	1/20
SCHEMBL12542945	0.80	1/20
SCHEMBL12690166	0.80	1/20
SCHEMBL15623717	0.80	1/20
SCHEMBL15622372	0.79	1/20
SCHEMBL12542696	0.78	1/20
SCHEMBL12543029	0.78	1/20
SCHEMBL12690189	0.77	1/20

Clinical trials — most relevant to NOTCH4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis	PHASE2	COMPLETED
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
Synergistic Pharmacologic Intervention for Prevention of ROP (SPIPROP Study)	PHASE2	COMPLETED
RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery	PHASE2	WITHDRAWN
NG2 and DLL3 CAR-T Cells Targeting Melanoma	PHASE1/PHASE2	RECRUITING
MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery	PHASE1	COMPLETED
Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC	PHASE1	RECRUITING
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors	PHASE1	RECRUITING
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma	PHASE1	COMPLETED
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia	PHASE1	WITHDRAWN
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)	PHASE1	COMPLETED
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors	PHASE1	COMPLETED
An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Pitt Hopkins Syndrome	PHASE1	RECRUITING
AusCADASIL: An Australian Cohort of CADASIL	nan	RECRUITING
Prospective Primary Human Lungcancer Organoids to Predict Treatment Response	nan	COMPLETED
Neurogenetic And Hemodynamic Of Migraine Aura And Pfo	nan	RECRUITING
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.	nan	RECRUITING
DNA Analysis of Tissue From Patients With T-Cell Acute Lymphoblastic Leukemia	nan	COMPLETED
Anodal tDCS in Chronic Migraine With Medication Overuse	nan	COMPLETED
Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma	nan	UNKNOWN
CADASIL Registry Study	nan	RECRUITING
MR Elastography in Intracranial Lesions: Feasibility & Accuracy	nan	ACTIVE_NOT_RECRUITING
Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents	nan	RECRUITING
B3 for NMD: Bench to Bedside and Back	nan	ENROLLING_BY_INVITATION
Does Notch Regulate Glioma Proliferation ?	nan	COMPLETED
Clinical Significance of DKK2 Protein in Cerebral Ischemia-reperfusion Injury	nan	UNKNOWN
Alzheimer's Disease Neuroimaging Initiative 4	nan	ENROLLING_BY_INVITATION
CIQTP Prolongation : Role and Mechanism in Sudden Cardiac Death	nan	COMPLETED
Development of New Biomarkers With Magnetic Resonance Imaging for Longitudinal Studies in CADASIL Angiopathy	nan	UNKNOWN
Predicting Pre-dementia	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a NOTCH4 binder may also engage these)

Protein	Name	Similarity
P31695	—	0.998	P31695 →
Q61982	—	0.980	Q61982 →
Q5VY43	—	0.979	Q5VY43 →
Q9R172	—	0.979	Q9R172 →
Q80YA8	—	0.976	Q80YA8 →
NOTCH3	Neurogenic locus notch homolog protein 3	0.973	landscape →
Q8K1E3	—	0.973	Q8K1E3 →
Q5IJ48	—	0.973	Q5IJ48 →
Q8VIK5	—	0.972	Q8VIK5 →
Q6ZWJ8	—	0.970	Q6ZWJ8 →
A2VEC9	—	0.968	A2VEC9 →
Q8CG65	—	0.967	Q8CG65 →
A4FV93	—	0.967	A4FV93 →
F12	Coagulation factor XII	0.967	landscape →
B2LW77	—	0.966	B2LW77 →
Q700K0	—	0.965	Q700K0 →
Q3U492	—	0.965	Q3U492 →
Q9Y219	—	0.964	Q9Y219 →
O97507	—	0.964	O97507 →
Q9BY79	—	0.964	Q9BY79 →
Q80YC5	—	0.963	Q80YC5 →
Q13444	—	0.963	Q13444 →
P98167	—	0.963	P98167 →
Q6UY11	—	0.963	Q6UY11 →
D3ZUK3	—	0.962	D3ZUK3 →
Q6ZRI0	—	0.962	Q6ZRI0 →
D3ZTE0	—	0.961	D3ZTE0 →
Q9NPY3	—	0.960	Q9NPY3 →
P15306	—	0.960	P15306 →
P06579	—	0.960	P06579 →